Drug-induced cardiotoxicity is a significant clinical issue, with many drugs in the market
being labeled with warnings on cardiovascular adverse effects. Treatments are often …

The development of human-induced pluripotent stem cell–derived cardiomyocytes (iPSC-
CMs) has opened a new era to address the challenge of improving drug-induced …

Introduction Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes is one of
the most widely used cell-based models that resulted from the discovery of how non …

Induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for
cardiovascular research by providing platforms to study the mechanisms of disease …

Billions of US dollars are invested every year by the pharmaceutical industry in drug
development, with the aim of introducing new drugs that are effective and have minimal side …

The drug development process, from discovery to safety studies, aims to bring efficacious
and safe drugs to market. Unfortunately, this ambition is often thwarted by unanticipated …

Safety pharmacology studies that evaluate drug candidates for potential cardiovascular
liabilities remain a critical component of drug development. Human induced pluripotent stem …

Drug attrition rates have increased in past years, resulting in growing costs for the
pharmaceutical industry and consumers. The reasons for this include the lack of in vitro …

Cardiovascular disease (CVD) complications have contributed significantly toward poor
survival of cancer patients worldwide. These complications that result in myocardial and …

Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …